Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin + Toripalimab vs Toripalimab in HER2-expressing high-risk muscle-invasive bladder cancer after cystectomy
ChiCTR2500111817Phase 3Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Nov 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in transitional cell carcinoma of the bladder (TCC) comparing Toripalimab monotherapy with Disitamab Vedotin + Toripalimab (2 arms). Primary endpoint: 2-year Disease-Free Survival. Started Nov 2025; status: recruiting.
02
Drugs
disitamab vedotintoripalimab
03
Conditions
transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on ChiCTR2500111817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111817.